Pharmacyclics — Technical Presentation (December 2013)
18 slides from Pharmacyclics's technical presentation, Dec 11, 2013
Slide 1: Ibrutinib in Combination With Bendamustine and Rituximab in R/R CLL/SLL
Ibrutinib in Combination With Bendamustine and Rituximab Is Active and Tolerable in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia: Final Results of a Phase 1b Study Jennifer R. Brown, MD, PhD}, Jacqueline Barrientos, MD?, Paul Barr, MD3, lan Flinn, MD, PhD
Slide 2: Bruton's Tyrosine Kinase (BTK)
Bruton’s Tyrosine Kinase (BTK) ™ BTK is an essential mediator of B-cell receptor signaling in normal and malignant B cells Chemokine-controlled cell migration pom aris, ro aave, ori era =
Slide 3: Ibrutinib binding and rationale for the PCYC-1108 study
™ Binds covalently to cysteine 481, with an initial half-life of 4-6 hours but 24-hour 0 target inhibition Ore ™ In PCYC 1102, ibrutinib monotherapy (420 mg, once-daily, oral dose): (s | — ORR 71% N AAY od, — Estimated 26-month PFS of 75% (Byrd NH et al, NEJM 2013) 2 ™ We present final results of a
Slide 4: A Phase 1b Study of Ibrutinib With BR or FCR in Patients With R/R CLL/SLL
PCYC 1108 A Phase 1b Study of Ibrutinib With BR or FCR in Patients With Relapsed/Refractory CLL/SLL ibrutinib 420 mg orally, once daily in 28d cycles + FCR (25 mg/m? d1-3 [F]; 250 mg/m? d1-3 [C]; 375 mg/m? cycle 1, 500 mg/m? cycles 2-6 [R]) for 6 cycles Investigator N=3 Choice ibrutinib 420 mg orall
Slide 5: Patient Demographics and Disease Characteristics
PCYC 1108 Patient Demographics and Disease Characteristics Characte: nn (%) as Hi Median age, years (range) 62 (41-82) 2 65 years 11 (37) Median number of prior treatments (range) 2 (1-3) >3 prior regimens 13 (43) Bulky disease (lymph nodes 2 5 cm) 16 (53) Rai stage III/IV (high risk) 16 (53) Hemogl
Slide 6: Patient Disposition and Treatment Summary
PCYC 1108 Patient Disposition and Treatment Summary Median follow-up, months (range) 15.8 (2.7-19.2) Median number of cycles of BR received (range) 6 (2-6) Median % total planned ibrutinib dose received 98 (82-100) (range) Patients continuing on long-term treatment, n (%) 21 (70) Patients discontinu
Slide 7: Treatment-Emergent AEs in ≥20% of Patients Regardless of Attribution
PCYC 1108 Treatment-Emergent AEs (TEAEs) in = 20% of Patients Regardless of Attribution Diarrhea | Z 70% Nausea i 67% Fatigue 47% Neutropenia 40% URTI 37% Peripheral edema 33% Constipation 30% Headache | 30% Vomiting 30% Arthralgia 27% Sinusitis 27% Dizziness 23% Insomnia mGradel 23% Muscle spasms m
Slide 8: TEAEs Grade ≥3 Occurring in Patients
PCYC 1108 TEAEs Grade 2 3 Occurring in 2 2 Patients 2 —_Neutropen'a_ |) iS 2 5 Thrombocytopenia |) ae Rash 10, 2 Fatigue 10 E o a = Cellulitis ah mGrade3 2 Febrileneutropenia |BU58H mGrade4 : : T T 1 0 10 20 30 40 50 ASH 2013, PCVC 1108, Brown et al.
Slide 9: Lymphocytosis: Absolute Lymphocyte Count
PCYC 1108 Lymphocytosis: Absolute Lymphocyte Count Change in Absolute Lymphocyte Count 300 ‘ — brutinib monotherapy (R/R 420mg) - 700 — BR+ Ibrutinib 6 _ o0 sot. } Bx 500 £8 400 = os 3 8 2 200 23 100 <8 57 oo = 400 +44 | -200 2 co ee ee a gi 2 & ¢ € ASH 2013, PCVC 1108, Brown et al.
Slide 10: Lymphocytosis: Lymph Node Size
PCYC 1108 Lymphocytosis: Lymph Node Size Change in Lymph Node Size o — Ibrutinib monotherapy (R/R 420mg) a — BR+ lbrutinib 4 -20 ‘oS 30 be £8 40 s SE so 23 £270 2 8 -70 8 ga -80 1 2 99 i -100 o Z ref ref ref re] re] 3 2 2 26° & &€ & & &§ &§ & & F F ASH 2013, PCVC 1108, Brown et al. is
Slide 11: Sustained Hematologic Improvement for Patients With Baseline Cytopenias
PCYC 1108 Sustained Hematologic Improvement for Patients With Baseline Cytopenias xe 100 g 90 @ 80 1 = 70 63 oO E 60 57 8 50 = 40 £ = 30 3 2» £ 10 a 04 : . 1 ANCS 1.5x1049/L Hgb < 11g/dL. Platelets < 100x1049/L (n=5/8) (n=5/7) (n= 8/14) Baseline Cytopenia Category ASH 2013, PCVC 1108, Brown et al. r
Slide 12: Overall Response Rate (ORR)
PCYC 1108 Overall Response Rate (ORR) 100 5 90 + "= Median treatment 20 4 16.7% duration on this study was 16 months, with an 70 4 10.0% ORR of 93.4% (28 responding patients [5 CR, 3 nPR]) ™ 1 patient achieved a PR Response Rate, % a r=) 1 30 | | 66.7% F t CR with lymphocytosis (not 20 Ta npR includ
Slide 13: ORR by Risk Feature
PCYC 1108 ORR by Risk Feature Baseline ECOG: 1 Baseline bulky disease 25 cm: v N Baseline cytopenia: sf N Number of prior systemic therapies: a >1 Del(17p): Positive Negative Del(11q): Positive Negative Baseline LDH: >350n/L $350p/L ASH 2013, PCVC 1108, Brown et al. 8
Slide 14: Progression-Free Survival
PCYC 1108 Progression-Free Survival — Ibrutinb +BR 2 06 2 2 < Boa e a 0.2 1+ Censored Number At Risk 30 29 26 23 23 18 Vv) 0.0 0 3 6 9 12 15 18 Months on Study 18/21 patients who continued on ibrutinib within the extension study are still on treatment ~1 year after the data-cut off without evidence
Slide 15: Limited Experience With Ibrutinib + FCR
Limited Experience With Ibrutinib + FCR Second Line " 3 patients treated; cohort closed due to a limited number of fludarabine-naive patients in the relapsed setting ™ Tolerable safety profile in 3 patients — One serious AE (gastritis) — All patients received all 6 cycles of FCR O 1 patient had a do
Slide 16: Conclusions
Conclusions ® The combination of BR + ibrutinib had an acceptable safety profile without significant safety concerns — No prolonged myelosuppression during cycle 1 — Response to BR + ibrutinib was associated with improved hemoglobin and platelet counts — Continuous treatment with ibrutinib after BR
Slide 17: Acknowledgments
Acknowledgments ™ We thank the patients who participated in this study and their families, as well as the investigators and their clinical and clinical trial staff members ® This study was conducted by Pharmacyclics, Inc ASH 2013, PCVC 1108, Brown et al. 7
Slide 18: Thank You
Thank You
Pharmacyclics — Technical Presentation (December 2013) on 6ix